Syed Naveed

Dr. Syed Naveed

Hematology and Oncology, Sheikh Shakhbout Medical City, Abu Dhabi, Abū Z̧aby, United Arab Emirates
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Indian Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SKSunilKumar Kota
SunilKumar Kota
GMGirijaBallav Mahapatra
GirijaBallav Mahapatra
SKSivaKrishna Kota
SivaKrishna Kota
Syed NaveedSyed Naveed
Syed Naveed
PTPrabhasRranjan Tripathy
PrabhasRranjan Tripathy
KMKirtikumarD Modi
KirtikumarD Modi
Background: Diabetes mellitus is associated with high cardiovascular risk. Carotid intima media thickness (CIMT) is used commonly as a noninvasive test for the assessment of degree of atherosclerosis. The objective of this study was to find out the cut-off point for CIMT for ischemic stroke in patients with type 2 diabetes mellitus (T2DM) and to correlate CIMT with various parameters like smoking, hypertension, lipid profile and duration of T2DM. Materials and Methods: A total of 80 subjects in the age group of 30-75 years (M:F = 57:23) were selected and divided into three groups, i.e. diabetes with ischemic stroke, diabetes and healthy subjects. All the participants were subjected to B-mode ultrasonography of both common carotid arteries to determine CIMT, along with history taking, physical examination and routine laboratory investigations including included fasting and 2-hour postprandial blood sugar, blood urea, serum creatinine, lipid profile, glycated hemoglobin, and microalbuminuria. Results: Patients with T2DM with or without ischemic stroke were found to have significantly higher prevalence of increased CIMT and a value greater than 0.8 mm was found to be associated with the occurrence of stroke. The mean carotid IMT of the group as a whole was 0.840 ± 0.2 mm. The mean carotid IMT was not significantly different between T2DM patients with or without ischemic stroke (1.06 ± 0.2 vs. 0.97 ± 0.26 mm, P = 0.08). However, the mean CIMT was significantly higher in diabetic subjects compared to healthy subjects (1.01 ± 0.28 mm vs. 0.73 ± 0.08, P = 0.006). Other parameters like higher age, smoking, hypertension, hyperlipidemia, low HDL cholesterol, the glycemic parameters and the duration of diabetes were independently and significantly related to CIMT. Conclusion: A high CIMT is a surrogate and reliable marker of higher risk of ischemic stroke amongst type 2 diabetic patients. Our study demonstrates the utility of carotid IMT as a simple non-invasive screening test for the assessment of atherosclerosis risk/prognosis in type 2 diabetics.

1 March 2025 in Journal of Medical Artificial Intelligence
Verified
Journal Article
Open access
PDF file
Syed NaveedSyed Naveed
Syed Naveed
MSMohamed Eltag Salih Saeed
Mohamed Eltag Salih Saeed
SHShakir Hussain
Shakir Hussain
IMImran Mirza
Imran Mirza
AAAmira Mahmoud Abdalla
Amira Mahmoud Abdalla
MYMohammad Yaqub
Mohammad Yaqub
Background: Diagnosis of leukemia relies on microscopic examination of suspected peripheral blood smears (PBS) by pathologists. However, this challenging and potentially error-prone process is further limited by the availability of pathologists. Developing a clinically applicable predictive artificial intelligence (AI) model offers a potential solution to these limitations. This study aimed to develop an AI model that predicts leukemia from microscopic images of peripheral blood smear. Methods: We developed hierarchical deep learning (DL) pipelines that were trained and validated on 7,255 high-power field (HPF) microscopy images collected from pre-diagnosed cases at our centre between January 2021 to August 2023. The proposed pipelines employed a high performing binary DL model in step 1 and multiclass DL models in step 2 to predict the label of each image from a slide, and then aggregate the results to provide a patient-level diagnostic prediction. This approach mimics the examination of PBS by trained hematopathologists, who examine multiple HPF patches under a microscope to predict the type of leukemia. The pipelines’ performance was assessed using F1 score, sensitivity, specificity, and accuracy, then compared against the three pathologists using Cohen’s kappa score. Results: The 3-class pipeline categorizes the slide as acute leukemia, chronic leukemia, or no leukemia. The F1 score, sensitivity, specificity, and accuracy were 94%, 94%, 95%, and 92% respectively. This pipeline outperformed the pathologists in all metrics. The agreement between this pipeline and pathologists ranged between 74–77%, while the agreement amongst the pathologists ranged from 82–87%. The 5-class pipeline categorizes the slide into acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphoblastic leukemia (CLL), and no leukemia. It achieved an F1 score of 77%, sensitivity of 80%, specificity of 94%, and accuracy of 70%. The 5-class pipeline outperformed pathologists in the CML and CLL classes but was inferior in other classes. The agreement between this pipeline and pathologists ranged between 52–53%, while the agreement amongst the pathologists ranged from 72–79%. Conclusions: Acute and chronic leukemia can be predicted with high sensitivity and specificity from whole-slide microscopic images of PBS by utilizing three deep-learning models in a hierarchical pattern and aggregating the results. This approach can efficiently predict and differentiate CLL from CML, but not ALL from AML. Applying cell segmentation in this level of the pipeline could improve the prediction in these classes. These pipelines can be applied in limited infrastructure settings to potentially identify types of leukemia with greater reliability.

3 May 2025 in International Journal of Hematology-Oncology and Stem Cell Research
Verified
Journal Article
Open access
Syed NaveedSyed Naveed
Syed Naveed
IAImrana Afrooz
Imrana Afrooz
FMFarooq Ahmed Mir
Farooq Ahmed Mir
AKAzmat Ali Khan
Azmat Ali Khan
NANada J.M.H Abdulla
Nada J.M.H Abdulla
SHShahrukh Hashmi
Shahrukh Hashmi
Background: Patients from regions without stem cell transplantation (SCT) facilities often seek treatment abroad and return home for post-transplant care. Although extensive data exist on graft-versus-host disease (GVHD) and its risk factors, information on international SCT patients returning to countries that lack transplant facilities and expertise is scarce and not well documented. Materials and Methods: We screened 149 transplant recipients and analyzed the data of 91 patients who received transplants abroad and were followed up at our center from January 2019 to December 2022. This observational study used data from electronic medical records and employed descriptive statistics, inferential tests, and relative risk calculations with forest plots to analyze the prevalence of GVDH and its key risk factors. Results: Of the recipients, 31.8% were residents of nine countries residing in the UAE, and 67.2% were UAE citizens. Adults comprised 48.3% of the recipients, whereas 51.7% were pediatric patients. Hematological malignancy was the most common indication (49%), primarily in adults. Siblings comprised the majority of donors (52.6%), followed by related (23.09%) and unrelated donors (8.9%). Most patients (69.2%) received HLA-identical transplants, followed by 21.9% who received haplo-identical transplants. Among adults, 62.2% developed GVHD compared to 26% of pediatric patients. Recipients from related HLA-identical donors had a 50% prevalence of GVDH, whereas those from unrelated identical donors had a 71% prevalence. The overall prevalence of GVDH was 50% in 87.9% of patients who received allogeneic SCTs. Conclusion: Despite favorable factors, such as young age and matched related donors, we found a high prevalence of GVDH. Ocular GVHD was less prevalent than expected, and lung GVHD was weakly correlated with established risk factors. Larger multicenter studies are needed to assess and confirm the effect of contributing factors.

1 January 2012 in International Journal of Trichology
Verified
Journal Article
Open access
PDF file
DGDilip Gude
Dilip Gude
Syed NaveedSyed Naveed
Syed Naveed
Int J Trichol, Official publication of The Hair Research Society of INDIA

24 July 2024 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
Syed NaveedSyed Naveed
Syed Naveed
ACAshish Vittalrao Chintakuntlawar
Ashish Vittalrao Chintakuntlawar
DVDeepti Vilasini
Deepti Vilasini
ASAisha Mohamed Al Salami
Aisha Mohamed Al Salami
RHRiad Al Hasan
Riad Al Hasan
ACAref Chehal
Aref Chehal
BACKGROUND Poly (ADP-ribose) polymerase inhibitors (PARPis) are approved as first-line therapies for breast cancer gene (BRCA )-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. They are also effective for new and recurrent ovarian cancers that are BRCA - or homologous recombination deficiency (HRD)-positive. However, data on these mutations and PARPi use in the Middle East are limited. AIM To assess BRCA /HRD prevalence and PARPi use in patients in the Middle East with breast/ovarian cancer. METHODS This was a single-center retrospective study of 57 of 472 breast cancer patients tested for BRCA mutations, and 25 of 65 ovarian cancer patients tested for HRD. These adult patients participated in at least four visits to the oncology service at our center between August 2021 and May 2023. Data were summarized using descriptive statistics and compared using counts and percentages. Response to treatment was assessed using Response Evaluation Criteria in Solid Tumors criteria. RESULTS Among the 472 breast cancer patients, 12.1% underwent BRCA testing, and 38.5% of 65 ovarian cancer patients received HRD testing. Pathogenic mutations were found in 25.6% of the tested patients: 26.3% breast cancers had germline BRCA (gBRCA ) mutations and 24.0% ovarian cancers showed HRD. Notably, 40.0% of gBRCA -positive breast cancers and 66.0% of HRD-positive ovarian cancers were Middle Eastern and Asian patients, respectively. PARPi treatment was used in 5 (33.3%) gBRCA -positive breast cancer patients as first-line therapy (n = 1; 7-months progression-free), for maintenance (n = 2; > 15-months progression-free), or at later stages due to compliance issues (n = 2). Four patients (66.6%) with HRD-positive ovarian cancer received PARPi and all remained progression-free. CONCLUSION Lower testing rates but higher BRCA mutations in breast cancer were found. Ethnicity reflected United Arab Emirates demographics, with breast cancer in Middle Eastern and ovarian cancer in Asian patients.

26 October 2023
Verified
Book Chapter
Closed access
PDF file
IHIbraheem Hamdi
Ibraheem Hamdi
HEHosam El-Gendy
Hosam El-Gendy
ASAhmed Sharshar
Ahmed Sharshar
MSMohamed Saeed
Mohamed Saeed
MRMuhammad Ridzuan
Muhammad Ridzuan
MYMohammad Yaqub
Mohammad Yaqub